Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-0877-2018

Drug recall · June 20, 2018

Maxzide-25 recall

Why: Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01

Lots / codes

Lot #: 3087136, Exp 5/20

Quantity
1,620 bottles
Company
Mylan Pharmaceuticals Inc., Morgantown, WV
Distribution
Product was distributed throughout the United States
Initiated
June 7, 2018 · Voluntary: Firm initiated
Classified
June 15, 2018
Reported
June 20, 2018
Ended
June 20, 2019
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Hydrochlorothiazide

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.